$TEM

Epstein David R sold $16K of TEM

Epstein David R sold 370 shares of Tempus AI, Inc. (TEM) at $43.40 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Epstein David R
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director under a pre-arranged 10b5-1 plan, which typically reduces interpretive value for near-term fundamentals.

02

Market read

Traders may log the transaction for insider-flow monitoring, but it is unlikely to drive a standalone repricing.

03

What to watch

The article does not state whether other insiders sold/bought, nor does it provide total insider ownership changes beyond the post-transaction share count.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-05 for a sale dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Tempus AI, Inc.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI director David R Epstein sold 370 shares at $43.40 under a pre-arranged 10b5-1 plan, totaling $16,058.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed sale size is modest relative to typical market moves.

Market effects

No clear sector read-through from a single, small 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with private information, so traders may still watch for follow-on filings or changes in insider activity.

Key entities

  • Tempus AI, Inc.

    Company whose director insider sale is disclosed on Form 4.

  • David R Epstein

    Director who sold 370 shares at $43.40 under a 10b5-1 plan.

Related articles

$TEMMed

Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.

$TEMMed

BTIG cuts Tempus AI stock price target to $70 on model update

BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.

$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

$TEMMedAI 8/10

Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.

$TEMMedAI 8/10

Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides

Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.